Works matching IS 03445704 AND DT 2025 AND VI 95 AND IP 1

Results: 58
    1
    2
    3

    Neurofilament light chain as a marker for neuronal damage: integrating in vitro studies and clinical findings in patients with oxaliplatin-induced neuropathy.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04773-w
    By:
    • Gehr, Nina Lykkegaard;
    • Mortensen, Christina;
    • Stage, Tore B.;
    • Pedersen, Malene Roland Vils;
    • Rafaelsen, Søren Rafael;
    • Madsen, Jonna Skov;
    • Olsen, Dorte Aalund;
    • Timm, Signe;
    • Jensen, Lars Henrik;
    • Hansen, Torben Frøstrup;
    • Finnerup, Nanna Brix;
    • Ventzel, Lise
    Publication type:
    Article
    4
    5
    6
    7
    8
    9
    10
    11

    Population pharmacokinetic analysis of bevacizumab in Japanese cancer patients with proteinuria: a prospective cohort study.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04769-6
    By:
    • Masuda, Takashi;
    • Funakoshi, Taro;
    • Horimatsu, Takahiro;
    • Masui, Sho;
    • Hira, Daiki;
    • Inoue, Marin;
    • Yajima, Kodai;
    • Nakagawa, Shunsaku;
    • Ikemi, Yasuaki;
    • Hamanishi, Junzo;
    • Takai, Atsushi;
    • Yamamoto, Shinya;
    • Matsubara, Takeshi;
    • Mandai, Masaki;
    • Seno, Hiroshi;
    • Yanagita, Motoko;
    • Muto, Manabu;
    • Terada, Tomohiro;
    • Yonezawa, Atsushi
    Publication type:
    Article
    12
    13
    14
    15

    Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04756-x
    By:
    • Liguori, Carolina;
    • Magi, Simona;
    • Mandolesi, Alessandra;
    • Agostini, Andrea;
    • Svegliati-Baroni, Gianluca;
    • Benedetti Cacciaguerra, Andrea;
    • Parisi, Alessandro;
    • Tiberi, Elisa;
    • Vivarelli, Marco;
    • Giovagnoni, Andrea;
    • Goteri, Gaia;
    • Castaldo, Pasqualina;
    • Berardi, Rossana;
    • Giampieri, Riccardo
    Publication type:
    Article
    16
    17
    18

    Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04764-x
    By:
    • Op 't Hoog, Catharina JP;
    • Rieborn, Amy;
    • Moes, Dirk Jan AR;
    • Hendrikx, Jeroen JMA;
    • van der Heijden, Michiel S.;
    • Franken, Mira D.;
    • van der Hulle, Tom;
    • van Kruchten, Michel;
    • Willemsen, Annelieke ECAB;
    • Koolen, Stijn LW;
    • Boerrigter, Emmy;
    • ter Heine, Rob
    Publication type:
    Article
    19
    20
    21

    Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial).

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04759-8
    By:
    • Hanrath, Maarten A.;
    • Banken, Evi;
    • van den Wildenberg, Sebastian A. H.;
    • van de Kerkhof, Daan;
    • Moes, Dirk Jan A. R.;
    • Boisdron-Celle, Michele;
    • van den Bosch, Bianca J. C.;
    • Bax, Ramon;
    • Bet, Pierre M.;
    • Maring, Jan Gerard;
    • Creemers, Geert-Jan M.;
    • van Hellemond, Irene. E. G.;
    • Deenen, Maarten J.
    Publication type:
    Article
    22
    23
    24
    25
    26

    Lipidomic profiling of plasma from patients with multiple myeloma receiving bortezomib: an exploratory biomarker study of JCOG1105 (JCOG1105A1)

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04752-1
    By:
    • Ri, Masaki;
    • Iida, Shinsuke;
    • Saito, Kosuke;
    • Saito, Yoshiro;
    • Maruyama, Dai;
    • Asano, Arisa;
    • Fukuhara, Suguru;
    • Tsujimura, Hideki;
    • Miyazaki, Kana;
    • Ota, Shuichi;
    • Fukuhara, Noriko;
    • Negoro, Eiju;
    • Kuroda, Junya;
    • Yoshida, Shinichiro;
    • Ohtsuka, Eiichi;
    • Norifumi, Tsukamoto;
    • Tabayashi, Takayuki;
    • Takayama, Nobuyuki;
    • Saito, Toko;
    • Suzuki, Yasuhiro
    Publication type:
    Article
    27
    28

    Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-024-04745-6
    By:
    • Krishnamurthy, Anuradha;
    • Wang, Hong;
    • Rhee, John C.;
    • Davar, Diwakar;
    • Moy, Ryan H.;
    • Ratner, Lee;
    • Christner, Susan M.;
    • Holleran, Julianne L.;
    • Deppas, Joshua;
    • Sclafani, Carina;
    • Schmitz, John C.;
    • Gore, Steve;
    • Chu, Edward;
    • Bakkenist, Christopher J.;
    • Beumer, Jan H.;
    • Villaruz, Liza C.
    Publication type:
    Article
    29

    Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-024-04746-5
    By:
    • Meertens, Marinda;
    • Giraud, Eline L.;
    • Hassan, Esbar;
    • Zielhuis, Sybrand W.J.;
    • Snels, Tiemen T.;
    • Desar, Ingrid M. E.;
    • Walraven, Janneke E. W.;
    • Wilgenhof, Sofie;
    • van Thienen, Johannes V.;
    • de Boer, Jan Paul;
    • Steeghs, Neeltje;
    • van Erp, Nielka P.;
    • Huitema, Alwin D. R.
    Publication type:
    Article
    30
    31
    32
    33

    WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-024-04731-y
    By:
    • Oliveira-Silva, João Marcos;
    • Oliveira, Leilane Sales;
    • Chiminazo, Carolina Berraut;
    • Fonseca, Rafael;
    • de Souza, Carlos Vinicius Expedito;
    • Aissa, Alexandre Ferro;
    • de Almeida Lima, Graziela Domingues;
    • Ionta, Marisa;
    • Castro-Gamero, Angel Mauricio
    Publication type:
    Article
    34

    WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-024-04731-y
    By:
    • Oliveira-Silva, João Marcos;
    • Oliveira, Leilane Sales;
    • Chiminazo, Carolina Berraut;
    • Fonseca, Rafael;
    • de Souza, Carlos Vinicius Expedito;
    • Aissa, Alexandre Ferro;
    • de Almeida Lima, Graziela Domingues;
    • Ionta, Marisa;
    • Castro-Gamero, Angel Mauricio
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42

    HER-2 SMASH.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-024-04726-9
    By:
    • Alandağ, Celal;
    • Öztürk, Ayşegül;
    • Yulak, Fatih;
    • Şahin İnan, Zeynep Deniz;
    • Karaca, Mustafa;
    • Lacın, Burak Batuhan;
    • Altun, Ahmet
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50